Anti-emetic effect of mosapride citrate hydrate, a 5-HT4 receptor agonist, on selective serotonin reuptake inhibitors (SSRIs)-induced emesis in experimental animals

Journal of Pharmacological Sciences

Volumn 121, Issue 1, 2013, Pages 58-66

  Mine, Yukiko ^a   Oku, Seiko ^a   Yoshida, Naoyuki ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

5 HT4 receptor agonist; Anti emetic effect; Emesis; Mosapride citrate hydrate; Selective serotonin reuptake inhibitors (SSRIs)

Indexed keywords

DOMPERIDONE; FLUVOXAMINE; MOSAPRIDE; ONDANSETRON; PAROXETINE; PIBOSEROD; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIEMETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM ELECTROPHYSIOLOGY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; EXPERIMENTAL DOG; GASTRIC VAGAL AFFERENT ACTIVITY; MALE; NONHUMAN; RAT; SHREW; SPECIES COMPARISON; STOMACH EMPTYING; SUNCUS MURINUS; VAGUS NERVE STIMULATION; VOMITING;

EID: 84873832071     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.12175FP     Document Type: Article

References (28)

1. Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000;85:11-28.
2. Ortiz J, Artigas F. Effects of monoamine uptake inhibitors on extracellular and platelet 5-hydroxytryptamine in rat blood: different effects of clomipramine and fluoxetine. Br J Pharmacol. 1992;105:941-946.
3. McManis PG, Talley NJ. Nausea and vomiting associated with selective serotonin reuptake inhibitors; incidence, mechanisms and management. CNS Drugs. 1977;8:394-401.
4. Bailey JE, Potokar J, Coupland N, Nutt DJ. The 5-HT3 antagonist ondansetron reduces gastrointestinal side effects induced by a specific serotonin re-uptake inhibitor in man. J Psychopharmacol. 1995;9:137-141.
5. Bergeron R, Blier P. Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors. Am J Psychiatry. 1994;151:1084-1086.
6. Yoshida N, Ito T, Karasawa T, Itoh Z. AS-4370, a new gastrokinetic agent, enhances upper gastrointestinal motor activity in conscious dogs. J Pharmacol Exp Ther. 1991;257:781-787.
7. Yoshida N, Kato S, Ito T. Mosapride citrate. Drugs Future. 1993; 18:513-515.
8. Hongo M. Initial approach and pharmacotherapy for functional dyspepsia - a large clinical trial in Japan (abstr). Gastroenterology. 2006;130:A-506.
9. Mizuta Y, Shikuwa S, Isomoto H, Mishima R, Akazawa Y, Masuda J, et al. Recent insights into digestive motility in functional dyspepsia. J Gastroenterol. 2006;41:1025-1040.
10. Okada T. Effectiveness of mosapride citrate to gastrointestinal side effects of fluvoxamine. Jpn J Psychiatric Treatment. 2001; 16:401-404. (text in Japanese)
11. Lanq IM. Noxious stimulation of emesis. Dig Dis Sci. 1994; 44(8 Suppl):58S-63S.
12. Carpenter DO. Neural mechanisms of emesis. Can J Physiol Pharmacol. 1990;68:230-236.
13. Cherian D, Parkman HP. Nausea and vomiting in diabetic and idiopathic gastroparesis. Neurogastroenterol Motil. 2012;24: 217-223.
14. Uneyama H, Niijima A, Tanaka T, Torii K. Receptor subtype specific activation of the rat gastric vagal afferent fibers to serotonin. Life Sci. 2002;72:415-423.
15. Droppleman DA, Gregory RL, Alphin RS. A simplified method for assessing drug effects on gastric emptying in rats. J Pharmacol Methods. 1980;4:227-230.
16. Mine Y, Yoshikawa T, Oku S, Nagai R, Yoshida N, Hosoki K. Comparison of effect of mosapride citrate and existing 5-HT4 receptor agonists on gastrointestinal motility in vivo and in vitro. J Pharmacol Exp Ther. 1997;283:1000-1008.
17. Ueno S, Matsuki N, Saito H. Suncus murinus: a new experimental model in emesis reseach. Life Sci. 1987;41:513-518.
18. Matsuki N, Torii Y, Ueno S, Saito H. Suncus murinus as an experimental animal model for emesis and motion sickness. In: Bianchi AL, Grelot L, Miller AD, King GL, editors. Mechanisms and control of emesis. Montrouge: John Libbey Eurotext Ltd, 1992. p. 323-329.
19. Okada F, Saito H, Matsuki N. Blockade of motion- and cisplatine-induced emesis by a 5-HT2 receptor agonist in Suncus murinus. Br J Pharmacol. 1995;114:931-934.
20. Fujiwara M, Yamashita N, Hayashi A, Imanishi T, Ichimaru Y, Baba J. Emetic reaction induced by a selective serotonin reuptake inhibitor, fluboxamine, in Suncus murinus. Pharmacometrics. 2000;59:39-46. (text in Japanese with English abstract)
21. Fujiwara-Sawada M, Imanishi T, Yoshida A, Baba J. Possible involvement of peripheral serotonin 5-HT3 receptors in fluvoxamine-induced emesis in Suncus murinus. J Pharm Pharmacol. 2003;55:271-274.
22. Torii Y, Saito H, Matsuki N. 5-Hydroxytryptamine is emetogenic in the house musk shrew, Suncus murinus. Naunyn Schmiedebergs Arch. Pharmacol. 1991;344:564-567.
23. Gaster LM. SB-207266. Drug Future. 1997;22:1325-1332.
24. Bhandari P, Andrews PLR. Preliminary evidence for the involvement of the putative 5HT-4 receptor in zacopride and copper sulfate-induced vomiting in the ferret. Eur J Pharmacol. 1991; 204:273-280.
25. King GL. Animal models in the study of vomiting. Can J Physiol Pharmacol. 1990;68:260-268.
26. Lang IM, Marvig J. Functional localization of specific receptors mediating gastrointestinal motor correlates of vomiting. Am J Physiol. 1989;256:G92-G99.
27. Fujitsuka N, Asakawa A, Hayashi M, Sameshima M, Amitani H, Kojima S, et al. Selective serotonin reuptake inhibitors modify physiological gastrointestinal motor activities via 5-HT2c receptor and acyl ghrelin. Biol Psychiatry. 2009;65:748-759.
28. Curran MP, Robinson DM. Mosapride in gastrointestinal disorders. Drugs. 2008;68:981-991.